163 results about "Sodium pyruvate" patented technology

The invention provides a porcine oocyte in-vitro maturation culture solution additive and application thereof, and belongs to the field of embryo engineering, and the additive contains taurine. The additive also contains sodium pyruvate, cysteine, glucose, NaHCO3, fetal calf serum, estradiol, pregnant horse serum gonadotropin and human chorionic gonadotropin. When the porcine oocyte in-vitro maturation culture solution added with the additive is used for culturing porcine oocytes in vitro, the ROS content in the porcine oocytes can be remarkably reduced, the oxidation resistance of the porcine oocytes can be improved, and the mitochondrial distribution of the oocytes can be improved, so that the development of the oocytes can be improved; the maturation of porcine oocytes and the development of early embryos are promoted. When the technology is applied to the pig assisted reproduction technology, the success rate and quality of embryo engineering can be improved; the pig oocyte in-vitro maturation culture solution added with the additive can improve the premature embryo division rate in parthenogenetic activation of the pig oocytes.

The invention discloses a serum-free culture medium for in-vitro proliferation of poultry muscle stem cells and application of the serum-free culture medium, and belongs to the technical field of cell engineering, a basic serum-free culture medium is DMEM-F12, a complete serum culture medium is a mixture of DMEM-F12 added with 10% of fetal calf serum and 1% of mycillin, and the volume ratio of a culture medium supplement to the basic culture medium is 1: 1000; the serum-free culture medium contains a supplement; the supplement comprises the following compositions: insulin, transferrin, fibroblast growth factor 2, epidermal growth factor, catalase, ethanolamine, vitamin B12, linoleic acid, linolenic acid, retinol acetate, tocopherol, L-alanine, L-proline, sodium selenite, sodium pyruvate, reduced glutathione, berberine hydrochloride and analogues thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to sodium pyruvate sustained-release gel nanoparticles based on redox response as well as a preparation method and application of the sodium pyruvate sustained-release gel nanoparticles. The preparation method comprises the following steps: adding modified gellan gum containing sulfydryl and catechol groups, phenylboronic acid modified gellan gum and sodium pyruvate into water to obtain a mixed solution; under the protection of inert gas, divalent metal salt and potassium persulfate are added into the mixed solution, stirring is performed for 3-5 h, after the reaction is finished, centrifugation is performed, precipitates are collected, washed and dried, and the composite material is obtained. Experimental results show that the sodium pyruvate sustained-release gel nanoparticles prepared by the invention can realize controlled release of drugs, reduce toxic and side effects caused by burst release of the drugs, improve the curative effect of the drugs and improve the bioavailability.

The mixture as the micronutrient composition is a combination of alpha-ketoglutaric acid, nicotinamide or nicotinic acid, L-proline, L-glutamine, L-citrulline, sodium pyruvate, pantothenic acid, L-cysteine or N-acetylcysteine, magnesium malate, magnesium citrate, and methionine. The mixture is effective for the treatment of diseases due to oxidative stress. More specifically, the mixtures and cores as micronutrient compositions are effective in reversing saccharification in diabetes mellitus.

The invention relates to the technical field of microorganisms, and discloses an induction method of VBNC state shigella, a resuscitation medium and application, and the resuscitation medium comprises Rpf recombinant protein, MgSO4, sodium pyruvate, vitamin B12, tryptone, glucose, dipotassium phosphate, monopotassium phosphate, sodium chloride and Tween 80. The resuscitation culture medium obtained by the invention can be used for successfully culturing Shigella in a VBNC state.

The invention aims to provide a preparation method of in-vitro cultured bear gall powder, which comprises the following steps: carrying out primary concentration, alcohol precipitation, macroporous adsorption separation, secondary concentration and freeze-drying purification on conversion liquid which is qualified in reaction to obtain the in-vitro cultured bear gall powder. Wherein the conversion liquid is prepared by mixing a chicken bile refined liquid with four-enzyme co-expression bacterial sludge or immobilized cells thereof, then adding NADP coenzyme, a surfactant and cosubstrates sodium pyruvate and dextrose monohydrate in a fixed proportion, and carrying out catalytic reaction at 25-30 DEG C for 2-24 hours; the obtained in-vitro cultured bear gall powder is subjected to whole-cell catalysis under proper conditions through whole cells expressing four enzymes or an immobilized cell form of the whole cells, the in-vitro cultured bear gall powder with stable TUDCA content is obtained, and no intermediate product T-7-KLCA residues exist.

The invention discloses a gelatin microcarrier lysate as well as a preparation method and application thereof. The gelatin microcarrier lysis buffer comprises lyase, a cell protective agent, a cell energy metabolism protective agent, an antioxidant, a buffer solution and a chelating agent. The gelatin microcarrier lysate has extremely strong protectiveness to cells, abandons damaging trypsin and EDTA, and innovatively adds a cell protection combination of a cell protective agent L-arginine, a cell energy metabolism protective agent sodium pyruvate and an antioxidant vitamin C, so that the cell survival rate (gt; 98%) and the retention rate (gt; the method is high in cell yield, good in safety and wide in range.

The invention belongs to the technical field of biological medicines, and particularly relates to a pyruvate preparation for treating non-small cell lung cancer and a preparation method of the pyruvate preparation. The pyruvate preparation is prepared from the following components in parts by weight: 0.03 to 0.05 part of sodium pyruvate, 0.01 to 0.03 part of synergist and 100 parts of water for injection. The preparation method of the synergist comprises the following steps: adding sodium pyruvate into a 3, 4-diaminophenol solution for reaction to obtain an intermediate 1; reacting the intermediate 1 with 4-chloro-1, 2-phenylenediamine to obtain an intermediate 2; reacting p-hydroxybenzaldehyde with propynyl chloride to obtain an intermediate 3; reacting the intermediate 3 with 1-azido-4-chlorobenzene to obtain an intermediate 4; and reacting the intermediate 2 with the intermediate 4 to obtain the synergist. Experimental results show that the synergistic agent and the sodium pyruvate are matched to achieve an excellent anti-tumor effect, and particularly, the selectivity of inhibition on non-small cell lung cancer tumors is shown.

The invention belongs to the technical field of sewage treatment, and particularly relates to a composite carbon source additive and a preparation method thereof. The composite carbon source additive comprises the following components in parts by weight: 30-40 parts of bagasse, 8-12 parts of a polyvinyl alcohol derivative, 2-4 parts of a functional filler, 5-8 parts of potassium citrate and 5-8 parts of sodium pyruvate, the preparation process of the polyvinyl alcohol derivative comprises the following steps: adding polyvinyl alcohol, 1, 3, 5-benzene trisulfonic acid, triethylamine and 4-dimethylaminopyridine into dichloromethane to react, filtering, washing and drying; the polyvinyl alcohol derivative is obtained. The composite carbon source additive can be slowly released in the denitrification process and continuously and stably provide a carbon source, the denitrification process is promoted, and the denitrification efficiency is improved.

The present invention belongs to the field of selective culture of microorganisms and relates to a detection medium for Burkholderia cepacia complex in a pharmaceutical water system. A detection medium for Burkholderia cepacia complex in a pharmaceutical water system, the formula (g / L) of the detection medium is: peptone 0.5 - 2.0 g, sodium pyruvate 1 - 4 g, carbon source 1 - 4 g, yeast extract 0.5 - 2.0 g, casein amino acid 1 - 4 g, magnesium sulfate 0.05 - 0.2 g, and the solvent is water. The inventor has screened a detection medium for Burkholderia cepacia complex in a pharmaceutical water system with special components. Through the culture experiment of Burkholderia cepacia complex, it is found that whether it is a standard strain or a wild strain isolated from a pharmaceutical water system, within the same culture time, the OD 600 value results of 1 / 10 TSB and R2A liquid media do not exceed 0.5, while the bacterial concentration in the detection (BCB) medium for Burkholderia cepacia complex in a pharmaceutical water system is significantly higher than that in 1 / 10 TSB and R2A liquid media.

The present invention belongs to the technical field of rapid detection of drug sensitivity for bacteria. Disclosed are an enrichment culture medium, and a preparation method therefor and the use thereof. The enrichment culture medium comprises the following raw materials in parts by mass: 15.0-20.0 parts of tryptone, 3.5-5.5 parts of peptone, 1.5-3.5 parts of glucose, 5.0-6.5 parts of yeast extract, 2.0-2.5 parts of dipotassium phosphate, 2.0-3.5 parts of disodium hydrogen phosphate, 1.0-1.5 parts of monopotassium phosphate, 2.5-7.5 parts of sodium chloride, 12.0-18.0 parts of proteose peptone, 15.0-22.0 parts of beef heart infusion powder, 8.0-12.0 parts of soya peptone, 1.0-5.0 parts of 0.1% nicotinamide adenine dinucleotide (NAD), 30-100 parts of newborn calf serum inactivated at 56°C for 30 min, 2.0-4.0 parts of mannitol, 3.0-5.0 parts of sodium pyruvate, 0.23-0.45 parts of cycloheximide, 0.8-2.0 parts of 0.05% bromothymol blue, 2.5-4.5 parts of 0.1% methylene blue, and 1000 parts of distilled water, with the pH value of 6.8-7.5. The enrichment culture medium is used to screen effective therapeutic drugs for bacterial diseases in poultry, and is convenient to use and has a single enrichment effect superior to that of respective selective enrichment broths of target bacteria. Therefore, the culture medium can realize rapid proliferation of common pathogenic bacteria in poultry.

The micronutrient composition is a combination of at least 6 ingredients, for example alpha-Ketoglutaric Acid, Niacinamide and / or Niacin, L-Proline, L-Glutamine, L-Citrulline and Sodium Pyruvate, preferably at least 11 ingredients, for example alpha-Ketoglutaric Acid, Niacinamide and / or Niacin, L-Proline, L-Glutamine, L-Citrulline, Sodium Pyruvate, Pantothenic Acid, L-Cysteine and / or N-acetyl Cysteine, Magnesium Malate, Magnesium Citrate and Methionine, more preferably all of the ingredients which are selected from the group consisting of: alpha-Ketoglutaric Acid, Niacinamide and / or Niacin, L-Proline, L-Glutamine, L-Citrulline, Sodium Pyruvate, Pantothenic Acid, L-Cysteine and / or N-acetyl Cysteine, Magnesium Malate and / or Magnesium Citrate, Methionine and / or S- Adenosyl-Methionine (SAMe), Methylsulfonylmethane (MSM), and Wormwood powder and / or extract. The composition is effectively used to treat diseases due to oxidative stress. More specifically, the micronutrient composition is effective in reversing glycation in diabetes and thus in treating diabetes.

The invention belongs to the field of biological medicine, and particularly relates to application of pyruvate in preparation of a medicine for treating lung biofilm infection. According to the application of the pyruvate in preparation of the medicine for treating lung biofilm infection, the pyruvate is a compound I, and the structural formula of the pyruvate is shown in the specification. The pyruvate disclosed by the invention is prepared from sodium pyruvate through chemical modification, has anti-infection activity and biocompatibility, and can be used for remarkably reducing the expression level of inflammatory factors and improving the treatment effect while reducing the dosage of medicines. The pyruvate disclosed by the invention has a wide application prospect in preparation of a medicine for treating lung biofilm infection.

The invention discloses a culture method for hypoxia culture of umbilical cord mesenchymal stem cells, which comprises the following steps: hypoxia pre-adaptive culture: inoculating umbilical cord mesenchymal stem cells in a culture medium containing bFGF (basic fibroblast growth factor), glutathione, astragalus polysaccharide and salidroside, and transferring the umbilical cord mesenchymal stem cells into a 5% O2 environment after the umbilical cord mesenchymal stem cells are preliminarily adhered to the wall in a normal oxygen environment; performing low-oxygen enrichment culture: replacing a second culture medium containing astragalus polysaccharide, salidroside, D-ribose, sodium pyruvate and D-glucose, and promoting efficient cell proliferation under 2% O2; performing function strengthening culture: adding tanshinone IIA and GSK-269962A, inducing cells to secrete VEGF under 1% O2, and maintaining high dryness. According to the method, through the synergistic effect of the three-stage gradient oxygen concentration and the specific serum-free culture medium, the cell proliferation multiple is remarkably increased, the total apoptosis rate is reduced, VEGF secretion is promoted, the multidirectional differentiation potential is reserved, the culture method is standardized in operation, the serum-free culture medium is definite in component, and a high-quality stem cell culture scheme is provided for the field of regenerative medicine.

The invention belongs to the field of cell culture, and discloses an osteosarcoma organ culture medium and a gelatin planting method. The following components are added into the osteosarcoma organ-like culture medium: a B27 additive, an N-2 additive, a GlutaMAX additive, casein amino acid, N-acetylcysteine, nicotinamide, vitamin C, sodium pyruvate, human gastrin, Wnt3A, R-spondin 1 protein, Noggin protein, activin A protein, Forskolin, Y-27632, SB202190, CHIR99021, A83-01, h-EGF, FGF-10, HGF, VEGF A, IGF 1, IL-6, cyan-streptomycin and fetal calf serum. The osteosarcoma organoid culture medium provided by the invention can promote organoid cells to maintain relatively high multiplication capacity and maintain self-renewal, so that the amplification efficiency and the modeling success rate of the organoid are greatly improved.

The invention discloses an umbilical cord mesenchymal stem cell serum-free culture medium, which is composed of a basic culture medium and additive components, and the additive components comprise, by final concentration, 5-20 [mu] g / mL of astragalus polysaccharide, 0.5-2.0 [mu] g / mL of salidroside, 0.1-0.5 [mu] g / mL of tanshinone IIA, 0.1-0.3 mg / mL of sodium pyruvate, 5-15 mM of D-ribose, 3-6 mg / mL of recombinant human albumin, and 5-10 [mu] g / mL of recombinant transferrin; the invention also discloses a method for culturing umbilical cord mesenchymal stem cells under the hypoxia condition by using the serum-free culture medium. The method comprises the steps of cell inoculation, culture under the hypoxia condition, subculture, cell passage and the like. The astragalus polysaccharide, the salidroside, the tanshinone IIA, the sodium pyruvate, the recombinant human albumin and the recombinant transferrin are added into the serum-free culture medium, so that nutrition supply and function maintenance of cells under a low-oxygen condition are guaranteed, the proliferation rate and the differentiation capacity of the cultured cells are improved, the apoptosis rate of the cells is reduced, and the survival rate of the cells is increased. Wide application prospects are realized in the fields of cell culture, regenerative medicine and the like.

The application provides a culture medium and a culture method of ovarian cancer primary cells. The culture medium comprises an MST1 / 2 kinase inhibitor, sodium pyruvate, forskolin, epidermal growth factor, gastrin, fibroblast growth factor 7, nicotinamide, SB431542, and fetal bovine serum. Compared with the existing culture method, the in-vitro culture using the culture medium of the application has higher amplification efficiency; the culture of the ovarian cancer primary cells using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the ovarian cancer primary cell culture.

Provided herein is a method for reducing a lactate spike and increasing titer in a fed-batch process for producing a protein of interest, comprising reducing pyruvate (e.g., sodium pyruvate) concentration in one or more feeds to cells in a bioreactor in the fed-batch process.

The present invention belongs to the field of cell culture and preservation, and specifically discloses a serum-free and DMSO-free mesenchymal stem cell cryopreservation solution, its preparation method and application. The cryopreservation solution contains the following components: a basic diluent 40-80 v / v%, a permeable cryoprotectant 5-20 v / v%, a non-permeable cryoprotectant 1-10 v / v%, a cell membrane protectant 5-20 v / v%, a cell activity additive 5-20 v / v%, and a plant-derived natural antioxidant composition; the basic diluent contains the following components: sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium bicarbonate, D-glucose, HEPES, and sodium pyruvate; the plant-derived natural antioxidant composition is cyanidin-3-O-glucoside C3G and epigallocatechin gallate EGCG; this cryopreservation solution does not contain serum or DMSO, and creatively combines the two plant-derived natural antioxidants C3G and EGCG. The sources and dosages of all components are clear, it does not contain any cytotoxic components, is easy to use, has a high cell recovery viability after cryopreservation, and has a wide range of applications.

The application discloses a chromogenic culture medium for detecting enteropathogenic Escherichia coli, which contains peptone, sodium pyruvate, sodium chloride, D-sorbitol, D-malic acid, bile salt, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium hydroxide, kaolin, bromothymol blue, crystal violet, polyethylene glycol and agar, and the rest is water. The chromogenic culture medium is simple in composition, convenient to prepare and use, and can be used for identifying enteropathogenic Escherichia coli EPEC according to the color of bacterial colonies, and has the advantages of specificity, high efficiency, rapidness, low cost, simple result judgment and the like, and has a wide application prospect in food safety monitoring.

The invention discloses a black soil prokaryote separation culture medium as well as a preparation method and application thereof. The isolation medium is prepared from a solution A, a solution B and a solution C, wherein the solution A comprises a nitrogen source, glucose, soluble starch and sodium pyruvate; the solution B comprises the following components: nitrilotriacetic acid and inorganic salt; the solution C comprises the following components: vitamins, lipoic acid and para aminobenzoic acid. The separation culture medium is designed and developed based on a complex microbial community structure in black soil, the nutrient concentration of the separation culture medium is low, compared with a conventional culture medium, prokaryotes separated by the separation culture medium are more in variety and better in effect, and the separation culture medium has important value and significance in development and utilization of black soil microbial resources.

The invention discloses a system for directionally differentiating chicken primordial germ cells into gametes in vitro and a regulation and control method, the system comprises a basic culture medium: based on DMEM / F12, adding 10% of fetal calf serum, 2% of chicken serum, 2 mmol / L of L-glutamine, 1 mmol / L of sodium pyruvate and 5.5 * 10 <-5 > mol / L of beta-mercaptoethanol; the spermatogonium induction culture medium further comprises BMP4, RA and GDNF; the oogonium induction culture medium also comprises BMP15, GDF9 and EGF (Epidermal Growth Factor). According to the system and the regulation and control method, the differentiation efficiency is improved, the culture period is shortened, and the number of cell clusters is remarkably increased.

The invention provides a THP-1 mononuclear cell culture medium and a culture method thereof. The THP-1 mononuclear cell culture medium comprises the following components: a complete culture medium, 8v / v%-12v / v% of fetal calf serum, 20mM-30mM of HEPES, 0.8 mM-1.2 mM of sodium pyruvate and 0.8 v / v%-1.2 v / v% of antibiotics. Wherein the HEPES is 2-4M HEPES mother liquor prepared by using a complete culture medium, the sodium pyruvate is 2-4M sodium pyruvate mother liquor prepared by using a complete culture medium, the complete culture medium is an RPMI 1640 culture medium, and the antibiotic is mycillin. The invention provides a series of optimized processes of a THP-1 cell culture method, passage, culture medium and the like, so that the THP-1 cell culture method is improved, the resuscitation state of the cryopreserved THP-1 cells is improved, and the phenomena of cell death and the like are reduced; besides, the THP-1 cell culture medium provided by the invention is optimized in formula and scientific in proportioning, the sensitivity degree of THP-1 cells to serum quality is reduced, and the good growth state of the THP-1 cells is further improved.

The invention relates to an establishment method and application of a micropterus salmoides muscle cell line, and belongs to the technical field of cell culture. The invention provides a culture solution which takes an M199 culture medium as a basic culture medium and further comprises sodium pyruvate, hydroxyethyl piperazine ethanesulfonic acid, beta-mercaptoethanol, penicillin, streptomycin and fetal calf serum. The culture solution provides optimal conditions for micropterus salmoides muscle cell culture, the culture cost is also reduced, the micropterus salmoides muscle cell line is established by adopting the culture solution, the method is simple and easy to operate and high in repeatability, the established cell line is good in stability, continuous passage and ultralow-temperature cryopreservation can be realized, the cell division speed is high, the passage time is short, the adherence rate is high, and the method is suitable for large-scale popularization and application. In the method, the micropterus salmoides muscle primary cell culture time is short, the number of obtained cells is large, the activity is good, and passage can be carried out in only 8 days.

The invention relates to the technical field of NK cell culture, and discloses an NK culture medium containing hypotaurine and application of the NK culture medium to improvement of NK cell proliferation and killing activity, and the NK culture medium comprises a basic NK cell culture medium and hypotaurine; the basic NK cell culture medium does not contain hypotaurine and comprises amino acid, vitamins, inorganic salt, trace elements, D-glucose and sodium pyruvate. When the basic NK cell culture medium is an RPMI1640 culture medium, the concentration of the hypotaurine is 0.1-1 mM; when the basic NK cell culture medium is an IMDM culture medium, the concentration of the hypotaurine is 0.4-4 mM. According to the scheme, the hypotaurine is added into the basic NK cell culture medium to obtain the NK culture medium, the NK culture medium can increase the number of NK cells when the NK cells are cultured in vitro, and the killing activity of the cultured NK cells on tumor cells is remarkably improved.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

A kit for in-vitro extraction of cell mitochondria and a method. The kit comprises an extraction liquid A, an extraction liquid B, an extraction liquid C and a preservation liquid, the extraction liquid A comprising EDTA, sodium lactate and sodium chloride, the extraction liquid B being a heparin solution, the extraction liquid C comprising mannitol, EDTA, sodium lactate and sodium chloride, and the preservation liquid comprising mannitol, EDTA, sodium lactate, succinic acid, sodium pyruvate and sodium chloride. Using the extraction liquids and the preservation liquid can better maintain the functions of mitochondria in vitro, thus prolonging the time span from extracting mitochondria to applying same to the bodies of patients, and helping to clinical application of mitochondrial transplantation.

The present invention belongs to the field of biomedicine, and specifically relates to a sodium pyruvate sustained-release nanoformulation based on pH response, and its preparation method and application. The preparation method of the nanoformulation: under the action of a catalyst, 2,3-dichlorobenzaldehyde, dopamine, and p-aminophenol are added to ethylene glycol dimethyl ether for substitution reaction to obtain compound 1; compound 1 and triethylamine are added to a phosphorus oxychloride solution, and stirred to react to obtain a compound with a phosphate group, an aldehyde group, and a catechol group; polylysine and aldehyde phenylboronic acid are reacted in a PBS buffer solution to obtain aldehyde phenylboronic acid-modified polylysine; sodium pyruvate is added to a solution of a compound with a phosphate group, an aldehyde group, and a catechol group to obtain a mixed solution, the mixed solution is homogenized, and a polylysine solution modified by aldehyde phenylboronic acid is added during the homogenization process, and a mixed solution is obtained after the homogenization is completed, and the mixed solution continues to be stirred and reacted, and the reaction solution is centrifuged, washed, and dried to obtain.

The invention belongs to the technical field of veterinary drugs, and particularly relates to an albendazole and ivermectin premix and a preparation method thereof. The albendazole and ivermectin premixing agent is prepared from the following raw materials in parts by weight: 5 to 10 parts of albendazole, 0.1 to 0.2 part of ivermectin, 8 to 15 parts of modified carboxymethyl cellulose, 5 to 10 parts of sodium pyruvate, 2 to 10 parts of lauryl sodium sulfate, 1 to 5 parts of sodium citrate, 10 to 20 parts of glucose and 60 to 70 parts of beta-cyclodextrin. The modified carboxymethyl cellulose and the sodium pyruvate in the premix can achieve a synergistic effect, and the redispersibility and the bioavailability of the albendazole and the ivermectin in the premix are further improved, so that the drug effect is improved. In addition, the premix also has good stability and can be stored for a long time.

The present invention belongs to the field of biomedical technologies, and particularly relates to the application of pyruvate in the preparation of a drug for enhancing the efficacy of lung cancer chemotherapy. The present invention provides a novel drug for treating lung cancer, namely Compound I obtained by structurally modifying sodium pyruvate. Experimental results show that this compound can significantly inhibit the proliferation of lung cancer cells A549 in mice, and at the same time has an inhibitory effect on the growth of human lung cancer A549 cell xenografts in nude mice, expanding the therapeutic potential of existing drugs and providing new treatment options for lung cancer patients. Its high efficiency in treating lung cancer is of great significance in improving the treatment effect and reducing the burden on patients.